Welcome to our dedicated page for Ocugen news (Ticker: OCGN), a resource for investors and traders seeking the latest updates and insights on Ocugen stock.
Ocugen, Inc. develops gene therapies for blindness diseases through a modifier gene therapy platform designed to address inherited and multifactorial retinal disorders. Company news commonly covers programs such as OCU400 for retinitis pigmentosa, OCU410 for geographic atrophy secondary to dry age-related macular degeneration, and OCU410ST for Stargardt disease.
Recurring updates include clinical trial data and dosing milestones, clinical and regulatory disclosures, operating and financial results, investor presentations, convertible-note financing, shareholder voting matters, capital-structure actions, and governance matters tied to the company's Nasdaq-listed common stock.
Ocugen reported its Q3 2022 financial results, highlighting the completion of enrollment for the Phase 2/3 COVAXIN™ trial and initiation of dosing in the OCU400 gene therapy clinical trial's third cohort. The company expanded its product pipeline with OCU500, a mucosal COVID-19 vaccine, and OCU410ST for Stargardt disease. As of September 30, 2022, Ocugen had $101.6 million in cash, expecting to fund operations through Q4 2023. Research and development expenses rose to $15.6 million. The net loss per share was $0.10, up from $0.05 in Q3 2021.
Ocugen, a biotechnology company, announced plans for a conference call on November 8, 2022, at 8:30 a.m. ET to discuss its Q3 2022 financial results and business updates. A pre-market earnings announcement will precede this call. Investors can join via specified dial-in numbers or through a webcast accessible on Ocugen's investor site. The company focuses on gene and cell therapies and vaccines, aiming to address multiple diseases, including retinal and infectious diseases.
Ocugen, a biotechnology company, announces its in-person Research & Development (R&D) Day on November 1, 2022, at the Nasdaq Market Site in New York City. The event aims to showcase Ocugen's innovative gene therapy and vaccine technologies, with panel discussions featuring leading experts such as Neena B. Haider, Mark Pennesi, and David Fajgenbaum. Attendees will gain insights into Ocugen's pipeline and business strategies. Registration is required, and a webcast replay will be available within 48 hours post-event.
Ocugen, Inc. (NASDAQ: OCGN) announced that the Independent Data and Safety Monitoring Board completed a review of the safety data for its OCU400 Phase 1/2 clinical trial and recommends proceeding to enroll subjects in Cohort 3. No safety concerns were noted in the ongoing trial, which focuses on treating inherited retinal degeneration. The company expects to complete Cohort 3 enrollment by Q4 2022. OCU400 aims to address unmet needs in patients with retinitis pigmentosa associated with NR2E3 and RHO mutations.
Ocugen, a biotechnology firm (NASDAQ: OCGN), announced participation in two key conferences on October 12, 2022. Dr. Shankar Musunuri will present their Modifier Gene Therapy platform for inherited retinal diseases at the 2022 Cell & Gene Meeting on the Mesa in Carlsbad, CA, while Dr. Robert J. Hopkins will discuss COVAXIN™, a COVID-19 vaccine candidate in Phase 2/3 trials, at the Vaccines Summit in Reston, VA. The company emphasizes its commitment to innovative gene and cell therapies aimed at improving global health.
Ocugen, a biotechnology company, announced that Dr. Shankar Musunuri, CEO and Co-Founder, will participate in a fireside chat at the Chardan 6th Annual Genetic Medicines Conference on October 4, 2022. The event takes place at the Westin Grand Central Hotel in New York City, from 8:30 to 8:55 a.m. ET. A live webcast will be available for viewers. Ocugen focuses on developing innovative gene and cell therapies, aiming to improve health and address unmet medical needs globally. For more details, visit their website.
Summary not available.
Ocugen announced on Sept. 16, 2022, that its Compensation Committee approved stock options and restricted stock units (RSUs) for five new hires, totaling 148,800 shares in stock options and 40,092 shares in RSUs. The options, granted at an exercise price of $2.17, have a ten-year term and vest over three years. This grant aligns with Nasdaq Listing Rule 5635(c)(4) as a material inducement for employment. Ocugen focuses on novel gene and cell therapies and vaccines, aiming to improve health and address unmet medical needs.
Ocugen, Inc. announced the publication of a comprehensive review on BBV152, commercialized as COVAXIN™, highlighting its effectiveness against COVID-19 and its variants, particularly Delta and Omicron. The review published in Frontiers in Immunology emphasizes the vaccine's immunogenicity, safety, and efficacy. BBV152 shows 77.8% protection from symptomatic COVID-19 and over 95% seroconversion in pediatric populations. COVAXIN™ has been authorized in 28 countries and accepted by over 85 for travel, enhancing its global accessibility. The company is investigating its use in adults in the U.S.
Ocugen, a biotechnology company, announces that Chief Scientific Officer Arun Upadhyay will speak at the 3rd Annual Gene Therapy for Ophthalmic Disorders Conference from September 13-16 in Danvers, Massachusetts. Dr. Upadhyay's presentation, scheduled for September 14 at 9:15 a.m. ET, will focus on the Modifier Gene Therapy Approach for Retinitis Pigmentosa. This event highlights Ocugen's commitment to advancing innovative therapies for retinal diseases. The company is actively developing gene and cell therapies to improve patient outcomes globally.